Nephrocare Health Services Reports 32.2% Revenue Jump for FY26

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
Nephrocare Health Services Reports 32.2% Revenue Jump for FY26
Overview

Nephrocare Health Services reported strong financial results for FY26, with revenue increasing 32.2% to ₹998.8 crore. The company also achieved significant growth in Adjusted EBITDA and Profit After Tax (PAT). This performance was driven by an increase in treatment volumes and a strategic expansion into international markets.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Nephrocare Health Services Reports Strong FY26 Financial Performance

Nephrocare Health Services Ltd. announced its audited financial results for the fiscal year ending March 31, 2026. The company posted consolidated revenue of ₹998.8 crore, a substantial 32.2% year-on-year (YoY) increase.

Key Financial Highlights

The company's strong performance was underscored by a 37.6% YoY rise in Adjusted EBITDA to ₹238.1 crore and an impressive 74.6% YoY surge in Adjusted Profit After Tax (PAT) to ₹128.3 crore.

Drivers of Growth

Nephrocare's revenue growth in FY26 was powered by a 16.6% YoY increase in the number of treatments performed. A key factor was the company's strategic pivot towards higher-margin international markets, which boosted their contribution to total revenue from 31.8% in FY25 to 41.8% in FY26. This strategic shift also positively impacted revenue per treatment, which grew by 13.3% YoY to ₹2,598.

Future Outlook and Innovation

Nephrocare Health Services is positioned to build on its recent success. The company is implementing digital innovations, including the deployment of its Reformmed.AI application in over 50 clinics, aimed at improving operational efficiency and patient care.

Potential Risks

Despite the positive results, the company faces potential risks such as increased competition in domestic and international markets, evolving regulatory landscapes in healthcare services, and the inherent challenges in scaling operations while maintaining high quality standards.

Key Metrics for FY26:

  • Revenue: ₹998.8 crore (32.2% YoY growth)
  • Adjusted EBITDA: ₹238.1 crore (37.6% YoY growth)
  • Adjusted PAT: ₹128.3 crore (74.6% YoY growth)
  • Treatments: 38,44,658 (16.6% YoY growth)
  • Revenue Per Treatment: ₹2,598 (13.3% YoY growth)
  • ROCE (Pre-Tax): 22.8%

What to Watch Next

Investors will be closely monitoring Nephrocare's progress in FY27. Key areas to track include its plans for deepening its presence in India and expanding its international operations, evaluating new geographic opportunities, and maintaining growth momentum through organic expansion and prudent capital allocation.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.